Valbonne Sophia Antipolis, France, September 10 - TxCell, a leading biotech company, today
announced that its Board of Directors has appointed Marc D. Beer as Chairman of the firm's
Supervisory Board. TxCell’s strategy is to develop a new class of autologous cellular
immunotherapy products that are uniquely designed to regulate a patient's own immune system.
TxCell is now entering the first-in-man stage (with a Phase I/IIa clinical trial in Crohn's disease)
and is also developing clinical applications in rheumatoid arthritis (RA).
"We are very fortunate to have Marc join as our new Chairman of our Supervisory Board, as he
has great experience and a keen understanding of the biotechnology industry in general and cell
therapy in particular. We are convinced that Marc has the business acumen and leadership skills
to support TxCell’s strategic development," commented Frederic Hammel, TxCell's CEO.
"I am excited and honored to be joining TxCell," stated Marc Beer, the newly appointed Chairman
of the Supervisory Board. "I believe in TxCell’s long-term potential benefits for patients with
chronic diseases. I look forward to working with the team to forge the road ahead", he added.
About Marc D. Beer
Marc D. Beer joined Cambridge MA-based ViaCell as its Chief Executive Officer in April 2000 and developed
the cell screening company through several rounds of private and stock market financing before organizing
its acquisition by PerkinElmer Inc. Prior to ViaCell, Marc held a number of senior management positions at
Genzyme, most recently serving as Vice President, Global Marketing for Genzyme Therapeutics. Before that,
Mr Beer held a variety of management roles at BioStar Inc. and Abbott Laboratories. Marc Beer has more
than 20 years' experience in P&L management, sales & marketing and R&D management in therapeutic,
surgical and in vitro diagnostics businesses. Mr. Beer received his B.S. in Business Administration from Miami
University, Oxford, in 1987
TxCell SA was spun out of INSERM (France's National Institute for Health and Medical Research) in 2001. The
company develops novel cell therapies for autoimmune and chronic inflammatory diseases based on the
biological properties of regulatory T lymphocytes (Tr1 cells). In 2007, the AFSSAPS (the French Agency for
Health Product Safety) authorized the company to start its first clinical trial of a Tr1 lymphocyte-based
therapy in Crohn's disease. The first results are expected at the end of this year. The firm is based in the
Sophia Antipolis technology park, near Nice in southern France. TxCell has recently moved into new premises
that are better suited to its future growth. www.txcell.com
firstname.lastname@example.org Tel: +33(0) 497 218 300
email@example.com Tel : + 33 (0) 664 189 959
firstname.lastname@example.org Tel : + 33 (0)1 41 22 07 32